Our CEO, Erik van den Berg recently sat down with John Simboli of the BioBoss podcast, where he discussed his career journey from AM-Pharma to Memo Therapeutics and what attracted him to the company – the opportunity to make a meaningful impact on patients’ lives. Drawing on his leadership experience in biotech, Erik explores Memo’s strong culture and the shared values that drive us.
The conversation explores potravitug, Memo’s first-in-class antibody therapy for BK polyomavirus (BKPyV) infection in kidney transplant recipients. Erik walks through the promising Phase II clinical trial results and explains the challenges that these patients face with limited treatment options. He also discusses the science behind Memo’s proprietary Dropzylla® platform, and how it identifies and isolates the most potent antibodies from the body’s natural immune response to viral infections and cancer.
Listen to the full podcast here:
